The specific IDH1 inhibitor, ivosidenib (AG-120), was tested, as a single agent, in a phase 1 clinical trial for patients with IDH mutation-positive advanced hematologic malignancies, including refractory/relapsed AML [37]. The gene discussed is IDH2; the disease is acute myeloid leukemia.